We describe the receptor binding and antagonistic properties of two novel nonpeptide antagonists, FR167344 (3-bromo-8-[2,6-dichloro-3
Kinins are members of a family of peptides that exhibit a variety of biological activities, including vasodilation, increased vascular permeability, contraction of smooth muscle cells, and activation of sensory neurons (1) (2) (3) . Bradykinin and kallidin (Lys-bradykinin) are released from high-and low-molecular-weight kininogens by the proteolytic action of kallikreins. Removal of the carboxyl terminus of these peptides by a carboxypeptidase generates des-Arg 9 -bradykinin and des-Arg 10 -kallidin, respectively (1, 2) . The biological effects elicited by kinins are mediated through the activation of two bradykinin receptor subtypes, B 1 and B 2 (1, 3, 4) . The cDNA sequences encoding these receptors have been reported (5-7). The two bradykinin receptors have seven hydrophobic segments and share a significant sequence similarity with other G protein-coupled receptors. B 1 receptor exhibits a rank order of binding affinities as follows: desArg 10 -kallidin Ͼ kallidin Ͼ des-Arg 9 -bradykinin Ͼ Ͼ bradykinin (4, 7); a rank order of potency for the B 2 receptor is bradykinin ϭ kallidin Ͼ Ͼ des-Arg 9 -bradykinin (4 -6). The involvement of kinins in the pathology of human diseases, including pain, inflammation, trauma, burns, shock, allergy, and some cardiovascular diseases, has been suggested by studies of animal models and humans (1) (2) (3) . Bradykinin receptor antagonists thus have therapeutic potential as novel analgesics and anti-inflammatory agents. To assess the disparate roles of the multiple receptor subtypes in each disease and to develop a clinically useful bradykinin antagonist, it is important to study the precise pharmacological properties of the two individual bradykinin receptors. Previously, several peptide and nonpeptide bradykinin receptor antagonists have been reported (4, 8, 9) . However, the accurate determination of the potencies of antagonists for individual receptors has been hampered by the existence of multiple receptor subtypes in tissues or cell preparations studied. Furthermore, it has become apparent that the ligand-receptor interaction should not be extrapolated across species without independent validation, because equivalent receptors between species can exhibit distinct pharmacological properties (4, 10) . The functional expression of a human cDNA clone for each bradykinin receptor subtype in the same cell type can provide a useful system to study the pharmacological profiles of antagonists for a single receptor subtype without any ambiguity resulting from the multiple receptor subtypes and from species differences in these receptors. FR167344 and FR173657 are novel nonpeptide bradykinin receptor antagonists that are effective on bradykinin-induced bronchoconstriction in guinea pigs and hypotensive response in rats (11) . 1 In this investigation, we examined the potencies, selectivities and antagonistic properties of FR167344 and FR173657 for the two human bradykinin receptor subtypes in transfected CHO cells. Fig. 1 .
Experimental Procedures
Receptor cDNA. The cDNA clones coding for the human B 1 and B 2 receptors were obtained by PCR performed on human aorta cDNA and kidney cDNA, respectively. To amplify the full-length B 1 and B 2 receptor-coding region, sets of primers were designed according to the published nucleotide sequences (6, 7) (B 1 : set 1, 5Ј-GGACTGGT-CTGTGCATGGCATCATCCTGGC-3Ј; 5Ј-GCGTCGACGGTTCAATG-CTGTTTTAATTCCGCC-3Ј; B 2 : set 1, 5Ј-CGGAATTCATCAATGTT-TCTGTCTGTTCGTGA-3Ј; 5Ј-AAGGGCAGCCAGCAGATGATG-3Ј; set 2, 5Ј-TTTCCTGATGCTGGTGAGCAT-3Ј; 5Ј-CGGGATCCTTACA-CAAATTCACAGCAGCCCT-3Ј). PCR amplification was performed by using the GeneAMP DNA amplification reagent kit according to the following schedule: B 1 , 30 sec at 94°and 5 min at 65°for 30 cycles; B 2 , 1 min at 94°, 2 min at 55°, and 3 min at 72°for 25 cycles followed by one cycle of 10 min at 72°. The resultant PCR products, the 1.1 kb pair B 1 receptor cDNA fragment and the 0.55 and 0.65 kb pair B 2 receptor cDNA fragments, were subcloned individually into pBluescript SK(Ϫ) after digestion with a mixture of SpeI and SalI (pBS-hB 1 ) and of EcoRI, SstI, and BamHI (pBS-hB 2 ), respectively. The identities of the obtained clones were confirmed by nucleotide sequence analyses (6, 7) .
Transfection and stable expression of the cloned bradykinin receptors. The CHO cell lines expressing the human bradykinin receptors were established according to the procedures described previously (12) . B 1 and B 2 receptor cDNA were subcloned individually into a eukaryotic expression vector containing the simian virus 40 early promoter and the mouse dihydrofolate reductase cDNA as a selective marker. The resultant plasmids were transfected into CHO (dhfr Ϫ ) cells by the calcium phosphate method (13) . Cell lines expressing a bradykinin receptor together with dihydrofolate reductase were selected in the ␣-minimal essential medium lacking ribonucleosides and deoxyribonucleosides, supplemented with 10% dialyzed fetal bovine serum. From selected cell populations, clonal cell lines were isolated by single cell cloning.
Ligand binding of bradykinin receptors. For the determination of the receptor densities and ligand binding selectivities of the bradykinin receptors expressed in clonal cells, the isolation of crude membranes and subsequent ligand binding assays were performed as described previously (14) (15) (16) Measurements of PI hydrolysis. PI hydrolysis was measured essentially as described previously (12) . CHO (dhfr Ϫ ) cells expressing individual bradykinin receptors were seeded in 12-well plates at a density of 1 ϫ 10 5 cells per well and cultured for 1 day. The cells were labeled with [ 3 H]inositol (1 Ci/ml) for 24 hr. The cells were washed twice with PBS containing 0.2% BSA and incubated with the same solution for 30 min and then with PBS containing 0.2% BSA and 10 mM LiCl for 30 min at 37°. Agonist stimulation was started by replacing the medium with fresh PBS (1 ϫ ϭ 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na 2 HPO 4 , and 1.5 mM KH 2 PO 4 , pH 7.4) containing 0.2% BSA, 10 mM LiCl, and test reagents. The reaction was terminated by 5% (w/v) trichloroacetic acid after incubation for 30 min at 37°. Separation of [ 3 H]inositol phosphates was carried out by BioRad (Richmond, CA) AG1ϫ8 chromatography essentially as described (17) . IP 1 , IP 2 , and IP 3 were eluted serially with 5 mM disodium tetraborate and 180 mM sodium formate, 0.1 M formic acid and 0.4 M ammonium formate and 0.1 M formic acid and 1.0 M ammonium formate, respectively. The radioactivity in the eluates was determined by a liquid scintillation spectrometer.
Data analysis. In the radioligand binding experiments, displacement data were fitted to the equation %B ϭ 100/{ 1 ϩ (x/IC 50 ) nH }, where %B is percentage of a bound radioligand to the total specific binding, x is the concentration of a competing ligand, IC 50 values represent the concentrations of ligands to inhibit the specific radioligand binding of receptors by 50%, and n H is the pseudo-Hill coef- 
Results and Discussion
Stable expression of the bradykinin receptors. The cDNA clones coding for the human B 1 and B 2 bradykinin receptors were obtained by PCR, and their identities were confirmed by nucleotide sequence analyses. There were some nucleotide differences between our B 1 bradykinin receptor cDNA clone and those of GenBank U12512, resulting in amino acid substitution. The amino acid sequence deduced from our B 1 receptor cDNA sequence showed substitutions of R (CGG) at residue 146 and RCGGR (AGGTGCGGGGGC-CGC) at residues 239-243, in place of the sequence predicted from GenBank data, G (GGA) and RVRGP (AGAGT-GCGGGGGCCG), respectively. The integrity of our nucleotide sequence was confirmed by the comparison with the sequence of B 1 receptor gene cloned from the human genomic DNA.
2 CHO (dhfr Ϫ ) cells were transfected with a vectordirecting expression of the cDNA for each of the human bradykinin receptor subtypes. A mouse dihydrofolate reductase cDNA was used as a selective marker that allowed receptor-expressing cell populations to grow in the medium lacking ribonucleosides and deoxyribonucleosides. More than 20 clonal cell lines that stably expressed bradykinin receptors at various levels were identified for each of the B 1 Receptor-binding studies of the bradykinin antagonists. The transfection and functional expression of cDNA clones for single receptor subtypes in the same cell type are useful for the accurate characterization of ligand-receptor interaction because uncertainties arising from the presence of multiple receptor subtypes and the species differences of the equivalent receptors can be eliminated successfully. We determined the potencies and selectivities of the nonpeptide antagonists, FR167344 and FR173657, in inhibiting specific radioligand binding to membranes prepared from CHO cells expressing each bradykinin receptor subtype. Competition curves of radioligand binding by the kinin peptides FR167344, FR173657, and Hoe140, a peptide antagonist, are presented in Fig. 2 . IC 50 values to inhibit specific radioligand binding to both receptor subtypes are summarized in Table 1 . When the receptor binding properties of kinins were exam- The present study reasonably predicts the pharmacological action of FR167344 and FR173657 in humans. We also have shown that FR167344 and FR173657 competed potently with the specific binding of [ 3 H]bradykinin to guinea pig ileum membranes with IC 50 values of 0.75 and 0.56 nM, respectively (11), 1 suggesting that the guinea pig receptor assay would be a suitable animal model.
Effects of FR167344 and FR173657 on bradykinininduced PI hydrolysis in clonal cells expressing the human B 2 receptor. The bradykinin receptors have been shown to mediate the stimulation of PI hydrolysis via a G protein (19) . We examined the effects of bradykinin application on IP 1 , IP 2 , and IP 3 formation in cells expressing the human B 2 receptor. The results of time course of PI hydrolysis are presented in Fig. 3 . Exposure to 100 nM bradykinin resulted in a substantial stimulation of inositol formation in clonal cells expressing the human B 2 receptor. IP 2 and IP 3 levels increased rapidly, whereas IP 1 was elevated slowly probably as a result of dephosphorylation of IP 2 and IP 3 . No bradykinin-induced response of PI hydrolysis was observed in untransfected CHO cells (data not shown). Next, we determined the dose-response curve of bradykinin for the stimulation of inositol phosphate formation in B 2 receptor-expressing cells (Fig. 4) . In this experiment, PI hydrolysis was measured by incubating cells with bradykinin for 30 min and monitoring the maximal formation of a mixture of IP 1 , IP 2 , and IP 3 . The EC 50 value of bradykinin was 1.1 nM, consistent with the binding affinity of bradykinin for the B 2 receptor (IC 50 ϭ 1.1 nM). This functional assay of B 2 receptor activation allowed the quantitative measurement of the potencies of antagonists for a single receptor subtype. Then, FR167344, FR173657, and Hoe140 were tested by measuring the ability to inhibit bradykinin-stimulated inositol phosphate formation in clonal cells stably expressing the human B 2 receptor. In this experiment, receptor-expressing cells were preincubated with different concentrations of the antagonist for 30 min. The amount of total inositol phosphates (IP 1 ϩ IP 2 ϩ IP 3 ) was determined after the activation of B 2 receptor with various concentrations of bradykinin for 30 min in the presence of the antagonist. In the presence of FR167344, FR173657, and Hoe140, the dose-response curves of bradykinin were shifted to the right in a concentration-dependent manner, and the maximal effect of bradykinin was significantly decreased (Fig. 4) . To estimate pA 2 values, the DRs were calculated from the horizontal distances between ascending parallel portions of the dose-response curves for bradykinin in the absence and presence of the antagonists. Schild analyses (18) of the antagonism of bradykinin-induced PI hydrolysis by FR167344 and FR173657 yielded estimated pA 2 values of 8.0 and 9.0, respectively. The values were comparable to that of Hoe140 (estimated pA 2 ϭ 8.6). The slopes of the regression lines for the antagonism by FR167344, FR173657, and Hoe140 were 1.2, 1.0, and 1.0, respectively. These results indicate that FR167344 and FR173657 selectively interact with the B 2 receptor and produce insurmountable inhibitory effects on bradykinin-induced PI hydrolysis. FR167344, FR173657, and Hoe140 itself showed no significant stimulatory effects on PI hydrolysis in B 2 receptor-expressing cells at the concentration of 10 M (data not shown). Therefore, the results demonstrate that FR167344 and FR173657 are potent, highly selective, and insurmountable nonpeptide antagonists of the human bradykinin B 2 receptor. The molecular mechanism underlying the interaction of these insurmountable antagonists with the B 2 receptor remains to be elucidated. However, the B 2 receptor antagonists described here differ markedly from the competitive antagonists we have described previously for the endothelin ET A receptor (20) and for the tachykinin NK 1 receptor (21), which induce a parallel shift in the dose-response curve of agonistinduced PI hydrolysis with no depression of the maximal response in CHO cells expressing ET A receptor and NK 1 receptor, respectively. In previous studies, Hoe140 has been shown to elicit a rightward shift in the dose-response curve of the bradykinin-induced contraction and a progressive decrease of the maximal response in guinea pig ileum (22) and trachea (23) , rabbit jugular vein (24, 25) , and rat uterus (26) . The noncompetitive behavior of Hoe140 has been suggested to be caused by a long-lasting interaction or, alternatively, an allosteric interaction with the receptor (22, 24) . We also have observed that FR167344 exhibits long-lasting inhibition of bradykinin-induced hypotension in rats. 1 The type of antagonism exhibited by FR167344 and FR173657 may be responsible, at least in part, for the tight binding to the human B 2 receptor.
FR167344 and FR173657 are highly selective antagonists for the B 2 receptor and lack agonist activity and, as such, will facilitate the elucidation of the physiological properties of the B 2 receptor. We have shown that FR167344 and FR173657 inhibit the bradykinin-induced contraction of guinea pig ileum with pA 2 values of 9.4 and 9.2, respectively (11).
1 These pA 2 values are comparable with those determined in this paper for the antagonism of PI hydrolysis. We also demonstrated that FR167344 and FR173657 inhibit bradykinininduced bronchoconstriction in guinea pigs and bradykinininduced hypotension and carrageenan-induced paw edema in rats (11) , 1 the actions of which are all believed to be mediated via B 2 receptor. Therefore, highly potent bradykinin receptor antagonists, such as FR167344 and FR173657, may have a therapeutic potential as novel anti-inflammatory agents. The use of cloned human receptors expressed in mammalian cells described in this study should facilitate the development of new bradykinin antagonists that will be valuable as human therapeutic agents. 
Nonpeptide Bradykinin Antagonists

